✦ LIBER ✦

Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta

✍ Scribed by Grazia Anna Niro; Alessia Ciancio; Giovanni Battista Gaeta; Antonina Smedile; Aldo Marrone; Antonella Olivero; Maria Stanzione; Ezio David; Giuseppina Brancaccio; Rosanna Fontana; Francesco Perri; Angelo Andriulli; Mario Rizzetto

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 253 KB
Volume: 44
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21296

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Monotherapy with Pegylated Interferon Al

Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C

✍ Gabriele Zoppoli; Giovanni Di Maio; Stefania Artioli; Cristina Robaudo; Monica B 📂 Article 📅 2008 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 89 KB

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues

✍ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Wan-Long Chuang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

accurate representation of the data is given in Table 1. 7. The major conclusion of this paper was that monitoring hepatitis C virus RNA levels and varying the duration of therapy can save resources without sacrificing rates of SVR. The authors used the Blackwelder test to test the noninferiority of

Treatment of chronic hepatitis E in live

Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b

✍ Elizabeth B. Haagsma; Annelies Riezebos-Brilman; Arie P. van den Berg; Robert J. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

Hepatitis E virus (HEV) infections are known to run a self-limiting course. Recently, chronic hepatitis E has been described in immunosuppressed patients after solid-organ transplantation. Besides the general recommendation to lower the immunosuppressive medication in these patients, there is curren

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated

Efficacy of low-dose intermittent interf

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy

✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

## Abstract The efficacy of interferon (IFN) monotherapy for non‐responders to pegylated interferon (PEG‐IFN) plus ribavirin (RBV) combination therapy is still unclear. To evaluate the impact of IFN monotherapy on biochemical response, 200 consecutive patients infected with HCV genotype 1b, who rec

Combined treatment with interferon alpha

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

✍ R. Schvarcz; Z. B. Yun; A. Sönnerborg; O. Weiland 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 2 views

Ten patients with chronic hepatitis C, six of whom had not responded and four of whom had responded in a non-sustained fashion to interferon-alpha treatment alone, were given interferon alpha-2b and ribavirin in combination during 24 weeks. Interferon alpha-2b was given subcutaneously, at a dose of